In a secondary analysis of the SISPCT trial (971 patients with sepsis or septic shock), each log10 rise in admission plasma H3.1 nucleosomes was associated with higher 28-day mortality (adjusted HR 1.48) and kidney replacement therapy need (adjusted HR 1.8).
Secondary analysisn = 971
Neumann et al. H3.1 Nucleosomes to Predict Renal Replacement Therapy and Mortality in Sepsis-A Secondary Analysis of the SISPCT Randomized Control Trial